Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Neurologic Complications of Heroin Addiction
Bull NY Acad Sci 49:4, Ritcher,R.W.,et al, 1973
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
JAMA Neurol 70:859-866, Savica, R.,et al, 2013
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Road Safety in Drivers With Parkinson Disease
Neurol 73:2112-2119, Uc,E.,et al, 2009
Impaired Visual Search in Drivers with Parkinsons Disease
Ann Neurol 60:407-413,387, Uc,E.Y.,et al, 2006
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Arch Neurol 58:1223-1227,1205, Alegret,M.,et al, 2001
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Safety and Efficacy of Pramipexole in Early Parkinson Disease
Parkinson Study Group, JAMA 278:125-1301997., , 1997
Frequency of Dementia in Parkinson Disease
Arch Neurol 42:428-431, Aarsland,D.,et al, 1996
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Unusual Clinical Presentations of Cortical-Basal Ganglionic Degeneration
Ann Neurol 40:893-900, Bergeron,C.,et al, 1996
Encephalopathy with Parkinsonian Features in Children Following Bone Marrow Transplantations and High-Dose Amphotericin B
Ann Neurol 37:810-814, Mott,S.H.,et al, 1995
Reversal of Amphotericin-B-Related Encephalopathy
Neurol 44:1183-1184, Balmaceda,C.M.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Extrapyramidalism in Alzheimer's Disease:Prevalence, Psychiatric and Neuropsychological Correlates
JNNP 57:1503-1509, Merello,M.,et al, 1994
Risk Factors for Nursing Home Placement in Advanced Parkinson's Disease
Neurol 43:2227-2229, Goetz,C.G.&Stebbins,G.T., 1993
Delayed Encephalopathy after Acute Carbon Monoxide Intoxication:MR Imaging Features & Cerebral White Matter Lesions
Radiology 184:117-122, Chang,K.H.,et al, 1992
Lesions of Basal Ganglia Due to Disulfiram Neurotoxicity
JNNP 55:925-929, Laplane,D.,et al, 1992
Preclinical Detection of Parkinson's Disease
Neurology Suppl 2, 41:5-921991., Koller,W.C.&Langston,J.W., 1991
Parkinsonism and Defects of Praxis Following Methanol Poisoning
JNNP 54:843-844, Mozaz,M.J.,et al, 1991
Cognitive Change Following MPTP Exposure
Neurol 40:261-264, Stern,Y.,et al, 1990
The Olfactory and Cognitive Deficits of Parkinson's Disease:Evidence for Independence
Ann Neurol 25:166-171, Doty,R.L.,et al, 1989
Cognitive Impairments Associated with Early Parkinson's Disease
Neurol 39:557-561, Levin,B.E.,et al, 1989
Dementia and Cognitive Impairment in Parkinson's Disease
JNNP 51:1498-1502, Girotti,F.,et al, 1988
Clinical & Biochemical Correlates of Bradyphrenia in Parkinson's Disease
Neurol 37:1130-1134, Mayeux,R.,et al, 1987
Raised Cerebrospinal-Fluid Copper Concentration in Parkinson's Disease
Lancet 2:238-241, Pall,H.E.,et al, 1987
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
The Clinical Syndrome of Striatal Dopamine Deficiency, Parkinsonism Induced by MPTP
NEJM 312:1418-1421, Burns,R.S.,et al, 1985
Depression, Intellectual Impairment & Parkinson Disease
Neurol 31:645-650, Mayeux,R.,et al, 1981
Levels of y-Aminobutyric Acid in Cerebrospinal Fluid in Various Neurologic Disorders
Arch Neurol 37:352-355, Manyam,N.V.B.,et al, 1980
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Dementia in Parkinson Disease:A Neuropathologic Study
Neurol 29:1209-1214, Hakim,A.M.,et al, 1979
Familial Fatal Parkinsonism with Alveolar Hypoventilation & Mental Depression
Ann Neurol 6:523-531, Purdy,A.,et al, 1979
Elevated Manganese Levels Associated with Dementia & Extrapyramidal Signs
Neurol 27:213, Banta,R.G.,et al, 1977
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Neurologic Manifest. of Infective Endocarditis:A Review
Stroke 4:958, Greenlee,J.E.,et al, 1973
Clinical Cases-Dx:Functional Approach to Neuroanatomy pp 477-490 Earl Lawrence House
McGraw Hill 1967., , 1967